## CDNA: CareDx, Inc - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.2% in lower entry zone (4.0-10.0%), top quartile (85th pct) cross-sectional ranking. Short-term MRS_5 (1.2%) confirms momentum alignment. Outperforming sector by 5.3%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($18.24)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of "Hold" from Brokerages**
- Source: MarketBeat | 20251222T061035 | Neutral | Relevance: 100%
- CareDx, Inc. (NASDAQ:CDNA) has received a consensus "Hold" rating from nine brokerages, with an average 12-month target price of $26.67. The company recently surpassed Q3 earnings and revenue estimates, reporting $0.28 EPS against a $0.13 consensus and $100.06 million in revenue, a 20.7% year-over-year increase. Several institutional investors, including Bamco Inc. NY and Deerfield Management Company, have also increased or initiated significant positions in CDNA, indicating growing institutional interest.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $18 | $14 | +29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 4 ($0.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 1 |

**Top Holders:**
- Blackrock Inc.: 9.3% (+2.3%)
- Vanguard Group Inc: 7.3% (-23.6%)
- BAMCO Inc.: 6.1% (+29.5%)
- State Street Corpora: 5.0% (+17.7%)
- Ophir Asset Manageme: 4.3% (+16.1%)

### Key Risks

1. High beta (2.54) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.1%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Forward P/E 22.9x attractive for 27% earnings growth. Quality metrics strong (ROE 24%, margin 20%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.39). Analyst sentiment positive (1 raises, avg +29%). Institutional flow bullish (9 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.1B |
| Beta | 2.54 |
| 52W Range | $10.96 - $25.95 |
| Short Interest | 13.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.12 |
| Forward P/E | 22.9 |
| Current P/E | 29.1 |
| YoY Growth | 26.9% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 6.3% to 5.2% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 85th percentile. MRS_5 at 1.2% confirms short-term momentum alignment. AM_20 at 5.8% shows strong absolute momentum above own 20MA. Outperforming sector by 5.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.19% (CS: 86) | Strong |
| RSI_14 | 63.6 | Neutral |
| MACD Histogram | -0.06 | Bearish |
| vs SMA20 | 1.058x | Above |
| vs SMA50 | 1.196x | Above |
| vs SMA200 | 1.225x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $20.02
- **Stop Loss:** $18.24 (8.9% risk)
- **Target:** $22.69 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 674
- **Position Value:** $13,493.48
- **Portfolio %:** 13.49%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-03-02 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.14 | $0.28 | +97.6% |
| 2025Q2 | $0.12 | $0.10 | -18.0% |
| 2025Q1 | $0.07 | $0.10 | +46.4% |
| 2024Q4 | $0.15 | $0.18 | +22.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*